Evaluation of neutrophil-to-lymphocyte ratio and immune response in patients vaccinated with Pfizer-Biontech vaccine
Introduction: Research on SARS-CoV-2 virus has focused on aspects such as treatment, virology, epidemiology and vaccine development. The efficacy of vaccines against SARS-CoV-2 is important for controlling the pandemic. This study assessed how the immune response is affected by age and gender, and its role in causing inflammation as measured by neutrophil-to-lymphocyte ratio (NLR) in vaccinated patients versus non-vaccinated COVID-19 negative patients.
Methodology: A case-control study was done involving 187 randomly selected patients who had undergone laboratory examinations to evaluate the SARS-CoV-2 IgG antibody titer and hematological parameters at 21 to 31 days after the second dose of vaccination. Patients were divided into case and control groups according to their vaccination status.
Results: The average age among the cases was 51 ± 13 years whereas the average age among the control group was 47 ± 15 years. In cases where the response to immunization was measured by SARS-CoV-2 IgG antibody, results had a median of 7.7 U/mL characterized by a large variation (p < 0.0001).
There was no significant difference based on age (p = 0.451) and gender (p = 0.622) in SARS-CoV-2 IgG antibody titers in patients vaccinated with two doses of Pfizer–BioNTech COVID-19 vaccine. In addition, there was no significant difference in NLR ratio between cases and controls (p = 0.117).
Conclusions: Our data showed that there is no inflammation at 21 to 31 days post vaccination with Pfizer-BioNTech COVID-19 vaccine, regardless of age and gender, based on the hematological parameters.
Copyright (c) 2022 Ridvana Mediu, Ariol Rama, Edmond Puca
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).